18 June 2015Americas

BIO 2015: Picking apart the Federal Circuit’s Sequenom ruling

On day three of the BIO International Convention, LSIPR spoke to Kevin Noonan and Donald Zuhn, partners at law firm McDonnell Boehnen Hulbert & Berghoff and authors of the Patent Docs blog, about the possible impact of the Federal Circuit’s Ariosa v Sequenom decision on the life sciences industry.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
2 July 2026   A federal court has ruled in a dispute between a clinical trial technology company and a psychedelic drug developer over allegations of trade secret misuse during a bidding process.
Americas
30 June 2026   Sandoz has filed FDA applications for generic versions of Eli Lilly’s blockbuster drugs, marking an early step towards potential competition in the fast-growing GLP-1 market.
Americas
25 June 2026   The Federal Circuit has brought Paxlovid’s infringement case to an end, serving as a reminder that even minor changes to patent language can have major consequences.